“I can remember the precise day, Jan. 24, when we made the decision at the breakfast table,” Ozlem Tureci, the chief medical officer of BioNTech said Thursday. “We knew we didn't have the capacity to conduct very quick clinical studies with more than 40,000 volunteers,” said Sahin. “We decided to make a huge investment, put the blinds down, close the doors and have the company work," Matthias Kromayer, general partner at Munich-based MIG AG, told The Associated Press. The company's biggest shareholder is Germany's Struengmann family, while Sahin and Tureci hold about 18% of the total. Once the pandemic is over, Tureci hopes to focus again on tackling cancer and other major diseases.

Source: ABC News December 17, 2020 14:10 UTC